Yu-San Kao

Yu-San Kao

Auto-generated profile, based on publicly available information

Yu-San Kao

Institute of Medical Microbiology and Hygiene, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
YKYu-San Kao
Yu-San Kao
MLMario Lauterbach
Mario Lauterbach
AKAleksandra Lopez Krol
Aleksandra Lopez Krol
UDUte Distler
Ute Distler
GGGloria Janet Godoy
Gloria Janet Godoy
TSTim Sparwasser
Tim Sparwasser
Metabolic reprogramming determines γδ T cell fate during thymic development; however, the metabolic requirements of interleukin (IL)-17A-producing γδ T cells (γδT17 cells) under psoriatic conditions are unclear. Combining high-throughput techniques, including RNA sequencing, SCENITH, proteomics and stable isotope tracing, we demonstrated that psoriatic inflammation caused γδT17 cells to switch toward aerobic glycolysis. Under psoriatic conditions, γδT17 cells upregulated ATP-citrate synthase to convert citrate to acetyl-CoA, linking carbohydrate metabolism and fatty acid synthesis (FAS). Accordingly, we used a pharmacological inhibitor, Soraphen A, which blocks acetyl-CoA carboxylase (ACC), to impair FAS in γδT17 cells, reducing their intracellular lipid stores and ability to produce IL-17A under psoriatic conditions in vitro. We pinpointed the pathogenic role of ACC1 in γδT17 cells in vivo by genetic ablation, ameliorating inflammation in a psoriatic mouse model. Furthermore, ACC inhibition limited human IL-17A-producing γδT17 cells. Targeting ACC1 to attenuate pathogenic γδT17 cell function has important implications for psoriasis management.

29 April 2022 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
STSen-Mao Tien
Sen-Mao Tien
PCPo-Chun Chang
Po-Chun Chang
YLYen-Chung Lai
Yen-Chung Lai
YCYung-Chun Chuang
Yung-Chun Chuang
CTChin-Kai Tseng
Chin-Kai Tseng
TYTrai-Ming Yeh
Trai-Ming Yeh
Dengue virus (DENV) which infects about 390 million people per year in tropical and subtropical areas manifests various disease symptoms, ranging from fever to life-threatening hemorrhage and even shock. To date, there is still no effective treatment for DENV disease, but only supportive care. DENV nonstructural protein 1 (NS1) has been shown to play a key role in disease pathogenesis. Recent studies have shown that anti-DENV NS1 antibody can provide disease protection by blocking the DENV-induced disruption of endothelial integrity. We previously demonstrated that anti-NS1 monoclonal antibody (mAb) protected mice from all four serotypes of DENV challenge. Here, we generated humanized anti-NS1 mAbs and transferred them to mice after DENV infection. The results showed that DENV-induced prolonged bleeding time and skin hemorrhage were reduced, even several days after DENV challenge. Mechanistic studies showed the ability of humanized anti-NS1 mAbs to inhibit NS1-induced vascular hyperpermeability and to elicit Fcγ-dependent complement-mediated cytolysis as well as antibody-dependent cellular cytotoxicity of cells infected with four serotypes of DENV. These results highlight humanized anti-NS1 mAb as a potential therapeutic agent in DENV infection.

12 October 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ADAyesha Dhillon-LaBrooy
Ayesha Dhillon-LaBrooy
KBKathrin L. Braband
Kathrin L. Braband
ETEshraq Tantawy
Eshraq Tantawy
FRFrancesca Rampoldi
Francesca Rampoldi
YKYu-San Kao
Yu-San Kao
TSTim Sparwasser
Tim Sparwasser

11 March 2022 in Vaccine
Verified
Journal Article
Closed access
HHHong-Jyun Huang
Hong-Jyun Huang
MYMartyr Yang
Martyr Yang
HCHsin-Wei Chen
Hsin-Wei Chen
SWShuying Wang
Shuying Wang
CCChih-Peng Chang
Chih-Peng Chang
SWShu-Wen Wan
Shu-Wen Wan